Quick Search:

is currently disabled due to reindexing of the ZORA database. Please use Advanced Search.
uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-56746

Regan, M M; Price, K N; Giobbie-Hurder, A; Thürlimann, B; Gelber, R D (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Research, 13(3):209.

[img]
Preview
Published Version
PDF
373kB

Abstract

The Breast International Group (BIG) 1-98 study is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one followed by 3 years of the other for postmenopausal women with endocrine-responsive early invasive breast cancer. From 1998 to 2003, BIG -98 enrolled 8,010 women. The enhanced design f the trial enabled two complementary analyses of efficacy and safety. Collection of tumor specimens further enabled treatment comparisons based on tumor biology. Reports of BIG 1-98 should be interpreted in relation to each individual patient as she weighs the costs and benefits of available treatments. Clinicaltrials.gov ID: NCT00004205.

Contributors:Varga, Z, Caduff, R [et al.]
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
DDC:610 Medicine & health
Language:English
Date:2011
Deposited On:24 Jan 2012 15:13
Last Modified:29 Nov 2013 08:56
Publisher:BioMed Central
ISSN:1465-5411
Publisher DOI:10.1186/bcr2837
PubMed ID:21635709
Citations:Web of Science®. Times Cited: 8
Google Scholar™
Scopus®. Citation Count: 10

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page